In addition to increasing understanding of the spatially acting immunosuppressive mechanisms in breast cancer, we believe that the current findings may also open new avenues for therapeutic targeting of FGF2-COX2 pathway as a mean to depolarize M(Gc)/CD163+ macrophages towards more M1-like, especially in treatment of metastatic breast cancers and primary TNBCs. The gene discussed is PTGS2; the disease is breast carcinoma.